Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Eidos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eidos Therapeutics Appoints Industry Leaders With Significant Development and Commercial Expertise to Board of Directors","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III"},{"orgOrder":0,"company":"Eidos Therapeutics","sponsor":"BridgeBio Pharma","pharmaFlowCategory":"D","amount":"$2,830.0 million","upfrontCash":"$175.0 million","newsHeadline":"Bridgebio Pharma and Eidos Therapeutics Announce Merger Agreement","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III"}]

    Find Clinical Drug Pipeline Developments & Deals by Eidos Therapeutics

    Menu

    Eidos Therapeutics

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Eidos Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Bridgebio Pharma and Eidos Therapeutics Announce Merger Agreement

              Details:

              Using this platform Eidos will be able to capitalize on BridgeBio’s global clinical development and regulatory expertise, its developing commercial infrastructure, and its broader capital base to reach more patients more effectively.

              Lead Product(s): Acoramidis Hydrochloride

              Therapeutic Area: Cardiology/Vascular Diseases Product Name: AG10

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: BridgeBio Pharma

              Deal Size: $2,830.0 million Upfront Cash: $175.0 million

              Deal Type: Merger October 05, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Eidos Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Eidos Therapeutics Appoints Industry Leaders With Significant Development and Commercial Expertise to Board of Directors

              Details:

              Eidos is developing acoramidis (formerly AG10) as a potentially best-in-class treatment option for ATTR patients.

              Lead Product(s): Acoramidis Hydrochloride

              Therapeutic Area: Genetic Disease Product Name: AG10

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable August 07, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY